Sweden's Peptonic Medical Q4 sales fall, margin improves on restructuring efforts

Peptonic Medical AB

27/02/2026 07:15

Overview

The Swedish medical tech firm's Q4 sales fell yr/yr due to company structure changes

Gross margin improved to 67% from 56% yr/yr

Company concluded reorganization and signed distribution deals in US, Canada, UK, Mexico

Outlook

Peptonic Medical plans geographical expansion to strengthen presence in existing and new markets

Company focuses on product development to broaden intimate care offering

Peptonic Medical revamps marketing strategy to enhance brand visibility and customer engagement

Result Drivers

RESTRUCTURING EFFORTS - Peptonic focused on streamlining operations by closing unprofitable subsidiaries and products, improving gross margins

DISTRIBUTION AGREEMENTS - Strategic distribution deals signed in US, Canada, UK, and Mexico to support future growth

FOCUS ON INTIMATE CARE - Company emphasized its focus on proprietary portfolio of intimate care products for growth

Company press release: ID:nWkr6Lhd5g

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Sales
SEK 14.78 mln
FY EPS
SEK 0
FY Gross Margin
67.00%
FY Gross Profit
SEK 9.95 mln
FY Operating Profit
-SEK 19.45 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)